2025年4月24日，歐盟食品安全局（EFSA）發布消息，歐盟食品安全局發布關于賴氨酸銅（copper bilysinate）作為所有動物飼料添加劑的授權更新申請的評估。
經過評估，專家小組得出結論，該添加劑在授權使用條件下對目標物種、消費者和環境都是安全的。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of copper bilysinate as nutritional feed additive for all species and categories. The additive is currently authorised for use in all animal species (3b411). The applicant has provided evidence that the additive, in powder or granule forms, complies with the conditions of the authorisation. The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) confirms that the use of copper bilysinate under the current authorised conditions of use is safe for the target species, consumers and the environment. Regarding user safety, both forms of the additive are not irritant to the skin, but the powder product is an eye irritant. Both forms of the additive should be considered skin and respiratory sensitisers. Inhalation and dermal exposure are considered a risk. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
經過評估，專家小組得出結論，該添加劑在授權使用條件下對目標物種、消費者和環境都是安全的。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of copper bilysinate as nutritional feed additive for all species and categories. The additive is currently authorised for use in all animal species (3b411). The applicant has provided evidence that the additive, in powder or granule forms, complies with the conditions of the authorisation. The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) confirms that the use of copper bilysinate under the current authorised conditions of use is safe for the target species, consumers and the environment. Regarding user safety, both forms of the additive are not irritant to the skin, but the powder product is an eye irritant. Both forms of the additive should be considered skin and respiratory sensitisers. Inhalation and dermal exposure are considered a risk. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
